Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of sotatercept added to background therapy in high-risk WHO functional class III/IV pulmonary arterial hypertension
MOH_2022-07-20_011924Phase 3Not yet recruiting
- Sponsor
- Acceleron Pharma Inc.
- Start
- Jun 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo + background therapy with Sotatercept + background therapy (2 arms). Planned start Jun 2022; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2022-07-20_011924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-20_011924.